AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06400134 — intervention group
Intervention type: OTHER
Intervention: Walking speed
Description: Walking speed was assessed with the 6-metre walk test. Speed was calculated by dividing each known distance by the time it took for each individual, on each trial, to walk from the start to the end points marked on the floor and then converting to m/s.
Study NCT06400134 — intervention group
Intervention type: OTHER
Intervention: Mobility
Description: The Time up Go test (TUG) was used for mobility. The risk of falling increases with increasing duration.
Study NCT06400134 — intervention group
Intervention type: OTHER
Intervention: Fraility
Description: Frailty assessment was performed using the FRAIL scale.The scale was scored by giving 0 or 1 point according to the answer given. The higher the score, the greater the fraility.
Study NCT05804916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface Guided Radiation Therapy (SGRT)
Description: SGRT and DIBH those two devices could be combined together to improve the accuracy in radiation therapy position and heart protection
Study NCT06634251 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This study is purely observational and does not involve any direct intervention. It utilizes retrospective analysis of computed tomography (CT) scans to simulate the fluoroscopic visualization and screw placement technique in the anterior column fixation corridor (ACFC) of the acetabulum. The objective is to define the optimal antegrade entry point and assess anatomical parameters without performing any physical intervention on the participants.
Study NCT06533748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or intravenously (IV).
Study NCT06533748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV.
Study NCT06533748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab
Description: Given IV.
Study NCT06533748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV.
Study NCT06533748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO.
Study NCT06533748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IT MHA
Description: Given Intrathecal (IT), Age adjusted.
Study NCT06533748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.
Study NCT06533748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT.
Study NCT06533748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, PO or intramuscular (IM).
Study NCT06533748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Given PO.
Study NCT06533748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase
Description: Given IV.
Study NCT06533748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV.
Study NCT06533748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO (participants intolerant to mercaptopurine).
Study NCT05799313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: At home removal
Description: Removal of PNE lead at home
Study NCT05799313 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In office removal
Description: Removal of PNE lead in the office
Study NCT05574101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Participants will undergo baseline imaging, followed by two doses of neoadjuvant cemiplimab at a dose of 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days). Then, participants will receive concurrent cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) concurrently with RT to 70 Gy in 35 fractions over 7 weeks. Thereafter, participants will receive 38 weeks of cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) for a cumulative total of 12 months of cemiplimab.
Study NCT05574101 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Participants will receive radiotherapy to 70 Gy in 35 fractions over 7 weeks concurrently with cemiplimab
Study NCT05292586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone Dipropionate/Formoterol Fumarate
Description: Available in pressurized inhalation solution BDP/FF 200/6 µg
Study NCT05292586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone Dipropionate
Description: Available in pressurized inhalation solution BDP 100 µg
Study NCT05024864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urea breath test (UBT)
Description: After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (breath bag). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and active H. pylori infection diagnosis is made based on previously established cut-off levels for H. pylori infection.~In patients tested positive, eradication therapy according to the national society of gastroenterology guidelines will be prescribed at the caring physician's discretion.~Control of successful H. pylori eradication 6 weeks after completed eradication therapy is recommended to the treating physician.~During the period without H. pylori screening, the study´s UBT equipment will not be available.
Study NCT05687383 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Safe breastfeeding pillow
Description: A randomized controlled trial
Study NCT05199454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Aerobic exercise training using a treadmill or a bike for 12 weeks, 3 times per week, 60 minutes per session.
Study NCT05687383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safe breastfeeding pillow
Description: A randomized controlled trial
Study NCT05699031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APP
Description: Patients allocated in the app-group will use the newly developed smartphone app te rehabilitate. 5 exercises are provided daily. Daily questionnaires will monitor exercise performance, VAS pain, household activities. Information modules will be sent at specific times.
Study NCT05699031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL THERAPY
Description: Patients allocated in the physio-group will go, twice a week, to a physical therapist of their choice to rehabilitate. The physical therapist will follow the general guidelines provided by the hospital (surgeon).
Study NCT06018038 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal Exercise Capacity, Maximal Oxygen Consumption (VO2max)
Description: Cardiopulmonary Exercise Testing (CPET)
Study NCT06255106 — intervention group
Intervention type: OTHER
Intervention: cast treatment
Description: Surgical intervention vs cast treatment
Study NCT04979910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: a monoclonal antibody (mAb) against interleukin 17A (IL-17A)
Study NCT06292013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lepodisiran Sodium
Description: Administered SC
Study NCT06292013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05457478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Qardio® smart scale Usage and Evaluation
Description: Weight monitored using a Qardio® smart scale
Study NCT05457478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05457478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05099003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a biopsy
Study NCT05099003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo a MRI
Study NCT05099003 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT05099003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given orally
Study NCT05988099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complex product
Description: 400 mg of chokeberry extract in liposomal formulation and L-arginine, vitamin E, vitamin A, folic acid, chromium
Study NCT05988099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chokeberry extract in liposomal formulation
Description: 400 mg of chokeberry extract in liposomal formulation
Study NCT05988099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chokeberry extract in traditional formulation
Description: 400 mg of chokeberry extract in traditional formulation
Study NCT05988099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05453838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: oral intake of one serving of the original and new product
Description: 1) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product
Study NCT04818671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: Subcutaneous injection with efgartigimod PH20 SC
Study NCT06475729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate-Free Mirikizumab
Description: Administered SC
Study NCT05165628 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CYP-006TK
Description: CYP-006TK is allogenic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs) or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing
Study NCT05433974 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample collection
Description: Blood sample collection : 2 X 6 mL
Study NCT04990102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Daunorubicin 8.8mg/m2 + cytarabine 20mg/m2
Study NCT05324956 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Individuals will not receive any interventions
Study NCT05250648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes
Description: In the arm with HIPEC, this will be performed with Mytomicin C, at a dose of 35 mg/m2 in peritoneal dialysis solution (2 liter/m2) for 90 minutes, with dose fractionation: 50% min 0, 25% min 30, 25% min 60
Study NCT04861636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthTRAC
Description: Behavioral weight management intervention targeting emotion regulation skill building. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
Study NCT04861636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBWC
Description: Behavioral intervention focused on behavioral weight control. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
Study NCT05153564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.34 mg/mL
Description: Semaglutide will be administered at a dose of 0.25, 0.50 or 1.0 mg as indicated on scale drum once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
Study NCT05153564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 3.0 mg/mL
Description: Semaglutide will be administered at a dose of 2.0 mg corresponding to the increment of 67 (pen injector units) as indicated on scale drum. once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
Study NCT05153564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0480-0389 10 mg/mL
Description: NNC0480-0389 will be administered at a dose of 0.23, 0.45 or 0.90 mL once weekly by s.c. (under the skin) injections for 14 weeks.
Study NCT05153564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0480-0389 30 mg/mL
Description: NNC0480-0389 will be administered at a dose of 0.60 mL once weekly by s.c. (under the skin) injections for 14 weeks.
Study NCT05153564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
Study NCT05250648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: complete cytoreductive surgery without HIPEC
Description: in the arm without HIPEC, only complete cytoreductive surgery will be performed
Study NCT05819203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healsea Babykids
Description: 7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
Study NCT05819203 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
Study NCT05437367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Stabilization exercises
Description: Therapeutic exercises
Study NCT05437367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Postural correction exercises
Description: Therapeutic exercises
Study NCT05437367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural correction exercises
Description: Therapeutic exercises
Study NCT06341868 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: KneeStim
Description: Participant will be randomized to either be in control or experimental group
Study NCT06341868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KneeStim
Description: Participant will be randomized to either be in control or experimental group
Study NCT04654117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultee-centered administrative consultation
Description: The consultee-centered administrative consultation model expressly focuses on supporting providers to increase EBP implementation within their specific setting.
Study NCT06218485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound-guided stent implantation after angiography-derived FFR-based decision-making
Description: The percutaneous coronary intervention will be performed by intravascular ultrasound (IVUS)-guided strategy after angiography-derived FFR-based decision-making:~1. PCI will be performed if angiography-derived FFR ≤0.80 and will be deferred if angiography-derived FFR >0.80.~2. If PCI is performed, PCI optimization using IVUS will be performed following the recommended criteria: ① Plaque burden at stent edge ≤55%; ② Minimal stent area ≥ 5.5 mm2, or minimal stent area ≥ distal reference lumen area
Study NCT06218485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional flow reserve-guided PCI strategy
Description: The percutaneous coronary intervention will be performed by fractional flow reserve (FFR)-guided strategy:~1. PCI will be performed if FFR ≤0.80 and will be deferred if FFR >0.80.~2. If PCI is performed, PCI optimization using FFR will be performed following the recommended criteria: ① Post-PCI FFR ≥ 0.88, or ② Post-PCI ΔFFR (\[FFR at stent distal edge\] - \[FFR at stent proximal edge\]) \< 0.05
Study NCT06394388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cuidando juntos
Description: Caregiver TLC program will be culturally tailored by including a focus on addressing cultural values to promote social connectedness and translated into Spanish (Cuidando Juntos).~Cuidando Juntos consists of 8 modules: stress management; behavioral activation; building resilience; building self-care skills; managing difficult emotions; reducing isolation; and two on understanding and responding to difficult behaviors of the PLWD.
Study NCT04874298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use Ginger and Peppermint oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
Study NCT04874298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peppermint
Description: Peppermint
Study NCT04933877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial plane block
Description: Serratus anterior plane block
Study NCT05346861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab plus chemotherapy
Description: Trastuzumab: 8 mg/kg loading dose followed by 6 mg/kg, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy Experimental: Pyrotinib +Trastuzumab + chemotherapy
Study NCT05651997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MACT
Description: * A biopsy of healthy cartilage is taken from a non-weight bearing area of the knee joint during an arthroscopic procedure.~* The biopsy is processed in the GMP accredited laboratory to isolate and amplify chondrocytes.~* The cells are seeded and cultured on a collagen matrix (Chondro-Gide®, Geistlich Pharma)~* The membrane is implanted and sutured onto the injured site.
Study NCT05651997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMT
Description: This treatment combines the microfracture procedure with the application of a bilayer matrix of porcine type I/III collagen (Chondro-Gide, Geistlich Pharma) and the supplementation of autologous bone.
Study NCT05119452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)
Description: The biological/targeted synthetic disease modifying anti-rheumatic drug will be discontinued in both arms at baseline
Study NCT05346861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with pyrotinib plus chemotherapy
Description: Pyrotinib: 400 mg po QD, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy
Study NCT03873428 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FES PET
Description: FES injection
Study NCT04894227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell）
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
Study NCT04729595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tempol
Description: Tempol 800 mg capsule will be administered at 400mg (2 capsules) two times daily for fourteen (14) consecutive days.
Study NCT04729595 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be administered orally (2 capsules) two times daily for fourteen (14) consecutive days.
Study NCT05604066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR) Elastography
Description: Magnetic resonance imaging (MRI) imaging technique that creates a visual map (Elastogram) to show the stiffness of body tissues
Study NCT05122936 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: XRXPY-based Obesity Wellness Intervention(SOWI)
Description: It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.
Study NCT05604066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI structural imaging
Description: MRI structural imaging will be done at the same time as MR elastography.